Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Glioma 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Medulloblastoma 7Lung Neoplasms 7Wilms Tumor 6Sarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Lymphoma 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma, Ewing 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Stomach Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2

Interventions

Cytarabine 18fludarabine phosphate 17Cyclophosphamide 12Busulfan 11Filgrastim 10Peripheral Blood Stem Cell Transplantation 9Etoposide 9Azacitidine 9Methotrexate 8Decitabine 8Antilymphocyte Serum 8Specimen Handling 7Daunorubicin 7Biopsy 7fludarabine 6Tacrolimus 6Stem Cell Transplantation 6Cyclosporine 6decitabine and cedazuridine drug combination 5Melphalan 5Idarubicin 5Topotecan 4Rituximab 4Radiotherapy 4Prednisone 4Mitoxantrone 4Methylprednisolone 4Injections 4venetoclax 3sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Myelodysplastic Syndromes × X-Rays × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡